Advertisement
Advertisement
Money /

Money News

Related Topics:
Banking & finance
Two-thirds of Hong Kong's ultra-rich expatriates said they plan to retire in the city due to strong financial benefits and boosts to their careers, according to a survey by St James's Place. Photo: Sun Yeung
Wealth management

Most ultra-rich expats plan to retire in Hong Kong, fuelled by financial perks

Two-thirds of the city’s ultra-rich expatriates wish to retire there because of financial benefits and career boosts, says St James’s Place.

34
Gold in Hong Kong

China gold ETFs see record US$2.91 billion outflow in June as risk appetite returns

Banking & finance

Southbound Stock Connect flows surge to record US$152b amid Hong Kong IPO boom

Millionaires, billionaires and trillionaires

What’s powering the rapid rise of Hong Kong’s ultra-wealthy class?

The city’s ultra-wealthy population jumped by more than 26 per cent in 2025 – roughly one super-rich individual for every 412 residents.

videocam
Hong Kong has nearly 18,300 ultra-high-net-worth individuals, defined as those with net assets exceeding US$30 million. Photo: Karma Lo
Hong Kong has nearly 18,300 ultra-high-net-worth individuals, defined as those with net assets exceeding US$30 million. Photo: Karma Lo
ETFs

Is FOMO driving South Korean investors to Hong Kong to cash in on AI and chips?

Some South Korean retail investors are turning to Hong Kong’s leveraged semiconductor ETFs for higher AI-driven returns.

IPO

As Musk becomes first trillionaire from SpaceX IPO, will next come from China?

As the initial public offering sees Musk become the first ever trillionaire, China is also seeing growth in its tech uber-rich.

17
Advertisement
Advertisement
Advertisement
China stock market

Emerging markets rebound on inflows as Xi-Trump talks eyed for momentum

Mainland China, Hong Kong stock markets may benefit from Xi-Trump meeting as renewed interest in AI shows investors keen to re-engage, analysts say.

videocam
People walk beneath a large screen showing stock exchange and economic data in Shanghai. Asia-Pacific markets have seen gains in recent months as geopolitical panic over the Iran war dissipates. Photo: EPA
People walk beneath a large screen showing stock exchange and economic data in Shanghai. Asia-Pacific markets have seen gains in recent months as geopolitical panic over the Iran war dissipates. Photo: EPA
Banking & finance

Hong Kong secures US$3.5 billion to fund Northern Metropolis and green projects

Global investors pile into city’s latest bond sale, with orders 7.6 times oversubscribed, backing its green finance ambitions.

China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Banking & finance

Global funds fuel Hong Kong IPO rebound as investors rebalance China portfolios

AI, robotics and energy storage firms make up most of the record-high IPO pipeline in Hong Kong, says Chan.

HKEX CEO Bonnie Chan Yiting speaks at the Chinese New Year Market Open Celebration at HKEX in Central, on February 20. Photo: Karma Lo
Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

A number of Chinese biopharmaceutical and biotech companies posted their first-ever annual profits in 2025. Photo: Shutterstock
A number of Chinese biopharmaceutical and biotech companies posted their first-ever annual profits in 2025. Photo: Shutterstock
Banking & finance

OKX Ventures, HashKey Capital back Vietnam crypto platform’s pilot scheme bid

Under pilot rules, at least 65 per cent of capital must come from institutional investors and foreign ownership is capped at 49 per cent.

Banking & finance

Mainland China and Hong Kong IPOs drive Citic to the top of banking fee rankings

Citic leads Asia-Pacific in fees in the first quarter as IPOs in Hong Kong and mainland China offset weaker debt and M&A activity.

Banking & finance

Stricter Chinese scrutiny of offshore vehicles a blow for tech IPO candidates

Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.

Many Chinese biotech and tech firms favour red-chip structures. Photo: Shutterstock
China’s private sector

Rights to antibody drug from China’s Keymed change hands in US acquisition

Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.

Gilead Sciences is one of many drug firms facing a revenue gap owing to expiring patents. Photo: Reuters
Gilead Sciences is one of many drug firms facing a revenue gap owing to expiring patents. Photo: Reuters
Banking & finance

Iran conflict drives fund managers to slash risk and hoard cash: BofA survey

Fund managers pile into cash at fastest pace since Covid-19 as geopolitical tensions, inflation replace AI as top concerns, bank finds.

Banking & finance

Chinese banks outpace rivals in Hong Kong wealth growth, Huatai HK CEO says

Booming listings and rising outbound investment demand are accelerating growth for Chinese players, SFC data shows.

Advertisement
Advertisement
Advertisement
China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Despite the headwinds, there is growing interest from multinational pharmaceutical companies in partnering with Chinese biotech firms. Photo: Getty Images
Despite the headwinds, there is growing interest from multinational pharmaceutical companies in partnering with Chinese biotech firms. Photo: Getty Images
Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.

Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

Banking & finance

Hong Kong family offices take long view despite Iran war, HKMA affiliate says

Survey shows family offices expanding risk management while maintaining strong investment exposure to Hong Kong and Asia.

Family offices are increasingly using hedging strategies and derivative instruments to manage portfolio risks, according to a survey. Photo: Sam Tsang
Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout
Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout
Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
Help preserve 120 years of quality journalism.
SUPPORT NOW